Completion of Joint-Venture: The Principals of NorthStar Capital Advisors are pleased to announce the completion on behalf of Everist genomics of a Joint-Venture with Bangalore headquartered Manipal Group, leveraging the mobile health revolution in India to commercialize Everist’s new cardiovascular diagnostics . Everist Genomics (EGI), a rapidly growing personalized medicine company, announced today that it has established a joint-venture company with the Manipal Group, one of the three largest healthcare sector companies in India. The joint venture will market EGI’s portfolio of diagnostic, prognostic and therapeutic selection technologies in India. Over 350 cardiologists attended a medical conference organized by one of India’s leading cardiac centers, Medanta Hospital in Delhi, at which EGI’s two new mobile health (mHealth) diagnostic systems for cardiovascular disease, AngioDefender and CardioDefender were introduced to physicians attending the conference. Over 300 physicians registered on a waiting list to receive EGI’s devices as they become available in India AngioDefender and CardioDefender integrate novel sensor technology with mobile digital services, smartphones and other mobile devices to provide flexible monitoring and diagnosis of cardiovascular conditions that traditionally have been limited to observation through legacy hospital diagnostic systems.
Everist Genomics: The Principals of NorthStar Capital Advisors are pleased to announce the completion on behalf of Everist genomics of an exclusive license to manufacture and market CardioDefender, the world's first hospital quality ECG on a smartphone, in 21 countries including India and the GCC region. CardioDefender (marketed as PocketECG in the United States and Europe) is FDA-approved and CE mark registered. Everist Genomics is a rapidly growing personalized medicine company. CardioDefender is a smartphone based ECG system which provides physicians and patients with hospital-quality heart rhythm monitoring outside of the hospital setting.
Genetics Squared The Principals of NorthStar Capital Advisors are pleased to announce the completion of the acquisition of a controlling interest in the Palo Alto, California headquartered Angiologix, Inc., by Ann Arbor, Michigan headquartered Genetics Squared, Inc. As part of the acquisition Genetics Squared also completed a financing.
Wearable Technologies Conference: Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.
Election to Board of Directors: The Principals of NorthStar Capital Advisors are pleased to announce the election of Alex Charlton (Managing Director, NorthStar) to the Board of Directors of Genetics Squared, Inc. a leading developer of innovative Molecular Diagnostics targeting cancer (click on the Navigation Menu, on the right of this page, to find out more)
Prospectus Now Available: NorthStar Capital Advisors announces access to qualifying Life Science sector companies to compelling tax incentives, a world-class free-trade zone (enabling the deferral, reduction and in some instances the elimination of all Customs duties and federal excise taxes), commercial infrastructure and investment capital(click on the Navigation Menu, on the right of this page, to find out more)
SpineView: NorthStar Capital Advisors, in collaboration with Windham Venture Partners, assisted in the completion of an $18 million financing for the California headquartered spinal tissue repair company, SpinView, Inc. Founded by Lewis C. Pell and Roy Chin (CEO and formerly of AFx Inc. and Stryker Corporation), SpinView is developing and commercializing an innovative, market disruptive portfolio of minimally invasive spinal repair devices. Earlier this year SpineView secured 2 FDA regulatory approvals and they have commenced sales in the United States.
Europa Partners Limited: Alex Charlton, Managing Director of NorthStar, has been appointed in a personal capacity as an independent Advisor to Europa Partners Limited, a corporate finance advisory firm headquartered in London. Wholly owned by the partners, Europa Partners provides objective corporate finance advice free from the conflicts inherent in a multi-product or capital market focused firm. Europa's partners have advised on transactions across five continents and have an extensive set of relationships with corporates, institutions and intermediaries worldwide.
Windham Venture Partners: NorthStar Capital Advisors have been appointed advisors to New York headquartered Windham Venture Partners. Windham Venture Partners is a Life Sciences technology commercialization firm. Examples of Windham's private equity investments include SpineView (minimally-invasive spinal tissue repair technology), GlySens (non-invasive, real-time blood glucose monitoring), Aura (light-activated Tissue Repair system uses a photo-responsive dye and visible light to create a instant water-tight union/seal) and Genetics Squared (molecular diagnostics and prognostics targeting cancer and cardiovascular diseases). Windham Venture Partners also act as founder, investor and initial management for portfolio companies.